|
|
 |
|
Viewing report
|
|
|
|
Commercial Perspectives: Pegylated Interferons - Leading the Way in HCV Therapy?
Datamonitor, April 2003, Pages: 102
Introduction
Alpha interferons have been the drug of choice for the treatment of hepatitis C since their discovery. However, the launch of pegylated interferons, namely Roche's Pegasys and Schering-Plough's Peg-intron, has begun to revolutionize hepatitis C therapy and the dynamics of this market.
Scope
Overview if the epidemiology of HCV and the existing patient potential for peginterferon-based therapies
Analysis of the impact of Roche’s new product launch, Pegasys, on the HCV market and particularly the preformance of Schering-Plough's Peg-intron
Comparison of the individual strengths of both companies along with their promotional efforts
Examination of potential drivers and barriers of growth for the pegylated interferons, with sales forecasts for the two leading products
Report Highlights
HCV incidence is decreasing, with the new cases in the US falling by approximately 88% since 1989, to 22,000 new infections by 2002.
Roche’s Pegasys and Schering-Plough’s Peg-intron dominate the HCV interferon market, generating 2002 sales of $24m (launched mid-year) and $810m (IMS Midas), respectively.
There are approximately 2 million HCV infected patients in Japan, creating a significant demand for peginterferon-based therapies. This market will be key to the overall success of Roche’s Pegasys.
Reasons to Purchase
Understand the competitive dynamics of the hepatitis C market
Evaluate the relative clinical advantages of pegylated interferon products
Analyze key promotional strategies and predict the future success of pegylated interferons
Customers who bought this item also bought
New Pegylated Interferons: Assessing the Impact of the New Longer Acting Interferons on the Hepatitis C Market
Pipeline Perspectives: Hepatitis B and C - Antivirals Challenge the Interferons?
Br Malls Participacoes Sa
Br. Holdings Corporation
Drugs of Tomorrow 2001: Hepatitis - The Succession of New Generation Therapies
Hepatitis C Virus And Therapeutics - A Global Update of Market Trends & Opportunities
Market Dynamics 2001: Hepatitis B&C - The Succession of New Generation Therapies
Treatment Algorithms 2002: Hepatitis B and C
Stakeholder Opinions: Hepatitis C - Small-molecule antivirals pave the way for triple therapy
Pipeline Perspectives: Hepatitis B and C - Antivirals Challenge the Interferons?
Hepatitis C Virus and Therapeutics - Global Strategic Business Report
Stakeholder Insight: Hepatitis B & C - Winning Battles But Not The War
|
|
|
|
